In Malaysia, researchers at the Universiti Sains Malaysia demonstrated that daily supplementation with its proprietary probiotic strain, Lactiplantibacillus plantarum K014, was well-tolerated and safe in healthy adults.
The study was funded by its commercial partner, Malaysian pharmaceutical and nutraceutical group Pharm-D Health Science Sdn. Bhd and involved 152 participants who took the daily probiotic or placebo for 6 months.
Further research is needed to investigate on potential health benefits from the use of L.plantarum K014 in dietary supplements and fermented foods. Its positive effects on gut health and the immune system have been well-documented while strains of the probiotic have also been reported to benefit weight loss, loose stools, cognitive performance and sleep.
Nevertheless, study has also shown adverse effects of L. plantarum in some cases to result in worsening IBS symptoms, and failing to improve intestinal permeability. This highlighted that the effects of probiotics can be strain-dependent and need specific safety and tolerance validation.
The specific strain L. plantarum K014 was isolated from local Malaysian cabbage by researchers at Universiti Sains Malaysia and is patented and marketed as Lassica KO14. The absence of adverse effects on the 152 participants based on blood, cholesterol, liver/kidney and immune testing supports the suitability of L. plantarum K014 for further investigation.
Nevertheless, the researchers acknowledged the study limitations, such as the small sample within a homogeneous population as well as respondents own reporting of outcomes. As such, more comprehensive studies can be conducted in the future.